Toby Pillinger1, Katherine Beck1, Cristian Gobjila1, Jacek G Donocik1, Sameer Jauhar1, Oliver D Howes2. 1. Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, England. 2. Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, England2MRC London Institute of Medical Sciences, Hammersmith Hospital, London, England3Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, England.
Abstract
IMPORTANCE: Schizophrenia is associated with an increased risk of type 2 diabetes. However, it is not clear whether schizophrenia confers an inherent risk for glucose dysregulation in the absence of the effects of chronic illness and long-term treatment. OBJECTIVE: To conduct a meta-analysis examining whether individuals with first-episode schizophrenia already exhibit alterations in glucose homeostasis compared with controls. DATA SOURCES: The EMBASE, MEDLINE, and PsycINFO databases were systematically searched for studies examining measures of glucose homeostasis in antipsychotic-naive individuals with first-episode schizophrenia compared with individuals serving as controls. STUDY SELECTION: Case-control studies reporting on fasting plasma glucose levels, plasma glucose levels after an oral glucose tolerance test, fasting plasma insulin levels, insulin resistance, and hemoglobin A1c (HbA1c) levels in first-episode antipsychotic-naive individuals with first-episode schizophrenia compared with healthy individuals serving as controls. Two independent investigators selected the studies. DATA EXTRACTION: Two independent investigators extracted study-level data for a random-effects meta-analysis. Standardized mean differences in fasting plasma glucose levels, plasma glucose levels after an oral glucose tolerance test, fasting plasma insulin levels, insulin resistance, and HbA1c levels were calculated. Sensitivity analyses examining the effect of body mass index, diet and exercise, race/ethnicity, and minimal (≤2 weeks) antipsychotic exposure were performed. DATA SYNTHESIS: Of 3660 citations retrieved, 16 case-control studies comprising 15 samples met inclusion criteria. The overall sample included 731 patients and 614 controls. Fasting plasma glucose levels (Hedges g = 0.20; 95% CI, 0.02 to 0.38; P = .03), plasma glucose levels after an oral glucose tolerance test (Hedges g = 0.61; 95% CI, 0.16 to 1.05; P = .007), fasting plasma insulin levels (Hedges g = 0.41; 95% CI, 0.09 to 0.72; P = .01), and insulin resistance (homeostatic model assessment of insulin resistance) (Hedges g = 0.35; 95% CI, 0.14 to 0.55; P = .001) were all significantly elevated in patients compared with controls. However, HbA1c levels (Hedges g = -0.08; CI, -0.34 to 0.18; P = .55) were not altered in patients compared with controls. CONCLUSIONS AND RELEVANCE: These findings show that glucose homeostasis is altered from illness onset in schizophrenia, indicating that patients are at increased risk of diabetes as a result. This finding has implications for the monitoring and treatment choice for patients with schizophrenia.
IMPORTANCE: Schizophrenia is associated with an increased risk of type 2 diabetes. However, it is not clear whether schizophrenia confers an inherent risk for glucose dysregulation in the absence of the effects of chronic illness and long-term treatment. OBJECTIVE: To conduct a meta-analysis examining whether individuals with first-episode schizophrenia already exhibit alterations in glucose homeostasis compared with controls. DATA SOURCES: The EMBASE, MEDLINE, and PsycINFO databases were systematically searched for studies examining measures of glucose homeostasis in antipsychotic-naive individuals with first-episode schizophrenia compared with individuals serving as controls. STUDY SELECTION: Case-control studies reporting on fasting plasma glucose levels, plasma glucose levels after an oral glucose tolerance test, fasting plasma insulin levels, insulin resistance, and hemoglobin A1c (HbA1c) levels in first-episode antipsychotic-naive individuals with first-episode schizophrenia compared with healthy individuals serving as controls. Two independent investigators selected the studies. DATA EXTRACTION: Two independent investigators extracted study-level data for a random-effects meta-analysis. Standardized mean differences in fasting plasma glucose levels, plasma glucose levels after an oral glucose tolerance test, fasting plasma insulin levels, insulin resistance, and HbA1c levels were calculated. Sensitivity analyses examining the effect of body mass index, diet and exercise, race/ethnicity, and minimal (≤2 weeks) antipsychotic exposure were performed. DATA SYNTHESIS: Of 3660 citations retrieved, 16 case-control studies comprising 15 samples met inclusion criteria. The overall sample included 731 patients and 614 controls. Fasting plasma glucose levels (Hedges g = 0.20; 95% CI, 0.02 to 0.38; P = .03), plasma glucose levels after an oral glucose tolerance test (Hedges g = 0.61; 95% CI, 0.16 to 1.05; P = .007), fasting plasma insulin levels (Hedges g = 0.41; 95% CI, 0.09 to 0.72; P = .01), and insulin resistance (homeostatic model assessment of insulin resistance) (Hedges g = 0.35; 95% CI, 0.14 to 0.55; P = .001) were all significantly elevated in patients compared with controls. However, HbA1c levels (Hedges g = -0.08; CI, -0.34 to 0.18; P = .55) were not altered in patients compared with controls. CONCLUSIONS AND RELEVANCE: These findings show that glucose homeostasis is altered from illness onset in schizophrenia, indicating that patients are at increased risk of diabetes as a result. This finding has implications for the monitoring and treatment choice for patients with schizophrenia.
Authors: D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker Journal: JAMA Date: 2000-04-19 Impact factor: 56.272
Authors: John W Newcomer; Dan W Haupt; Robert Fucetola; Angela K Melson; Julie A Schweiger; Benjamin P Cooper; Gregg Selke Journal: Arch Gen Psychiatry Date: 2002-04
Authors: Oliver D Howes; Ajay Bhatnagar; Fiona P Gaughran; Stephanie A Amiel; Robin M Murray; Lyn S Pilowsky Journal: Am J Psychiatry Date: 2004-02 Impact factor: 18.112
Authors: Santosh Lamichhane; Alex M Dickens; Partho Sen; Heikki Laurikainen; Faith Borgan; Jaana Suvisaari; Tuulia Hyötyläinen; Oliver Howes; Jarmo Hietala; Matej Orešič Journal: Schizophr Bull Date: 2021-01-23 Impact factor: 9.306
Authors: Jakub Tomasik; Santiago G Lago; Javier Vázquez-Bourgon; Sergi Papiol; Paula Suárez-Pinilla; Benedicto Crespo-Facorro; Sabine Bahn Journal: JAMA Psychiatry Date: 2019-08-01 Impact factor: 21.596
Authors: Teodor T Postolache; Laura Del Bosque-Plata; Serge Jabbour; Michael Vergare; Rongling Wu; Claudia Gragnoli Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2019-02-06 Impact factor: 3.568
Authors: Rodrigo B Mansur; Gabriel R Fries; Mehala Subramaniapillai; Sophia Frangou; Fernanda G De Felice; Natalie Rasgon; Bruce McEwen; Elisa Brietzke; Roger S McIntyre Journal: J Psychiatr Res Date: 2018-10-27 Impact factor: 4.791
Authors: Rodrigo B Mansur; Gabriel R Fries; Alisson P Trevizol; Mehala Subramaniapillai; Julie Lovshin; Kangguang Lin; Maj Vinberg; Roger C Ho; Elisa Brietzke; Roger S McIntyre Journal: Eur Neuropsychopharmacol Date: 2018-11-06 Impact factor: 4.600
Authors: Liisa Leppik; Madis Parksepp; Sven Janno; Kati Koido; Liina Haring; Eero Vasar; Mihkel Zilmer Journal: Eur Arch Psychiatry Clin Neurosci Date: 2019-01-02 Impact factor: 5.270